Reposting for anyone who missed the below - places still available - great speakers confirmed - Programme in link - should be a fun and informative day! @glasgowctu.bsky.social

📚 Weekend reading recommendation:
Browse the #EASD2025 Final Programme - 300+ pages packed with exciting content, from basic to clinical #diabetes #research.

📖 Explore the programme: www.easd.org/uploads/EASD...

🎟️ Register now: www.easd.org/annual-meeti...

#AnnualMeeting #ScientificProgramme

Please join us soon in Glasgow for a 1-day course on “How to be a Great Chief Investigator” featuring trialists and CTU experts from around Scotland - supported by UKCRC - *Thursday 9th October* - open to all! @bleedingstroke.bsky.social @kerryhood.bsky.social @glasgowctu.bsky.social registration >

Hi! We will discuss your article tonight 9 pm EST (I know, difficult hour for your timezone) #NephJC

Here is our take on your article www.nephjc.com/news/metform...

Real-world tirzepatide use in #T2D in 🇺🇸

🔹 Initiation: 84% start at ≤5 mg, 69.6% ⤴️ dose within 6m

🔸 Dosing at 6m: 56.5% remain <10 mg

🔹 Persistence: 73.3% still on treatment at 6m

🔸 Discontinuation: 26.7% stopped, 29.1% restarted

👉 Persistence high, slower titration the norm

🔗 ggdocs.co/0z0q43

SGLT2is were more cardioprotective in older people (despite smaller reductions in HbA1c) and GLP-1 RAs were more cardioprotective in younger people @uofglasgow.bsky.social

From David McAllister of University of Glasgow School of Health and Wellbeing using individual patient data meta-analysis and meta-regression . . .

Olympic swimming champion Gary Hall Jr., a hero to the #type1diabetes community, has lost his home and medals in the California fires. Gut wrenching.

Closing date for this opportunity at the University of Glasgow is approaching fast - if you think you could be the right person, please get in touch!

www.findaphd.com/phds/project...

www.ncbi.nlm.nih.gov/pubmed/39488... Lancet review

Nice conceptual model of “how everything is related to everything else” by Sven Francque (UZA, Antwerp, Belgium) at the Joint EGIR-MASLD EASD Study Group Meeting (insulin resistance/ metabolic liver disease), Lille, France today in a lecture on new EASL-EASD-EASO guidelines for MASLD

Finally published today! My heart is in my throat, but I hope that some of you will read it and find it interesting.
And I’d be very grateful for any reviews (Goodreads, Amazon…)

🏆Exciting news! ATTEST-2 has been selected as
ESOS Paper of the Month. The study explores tenecteplase vs alteplase in acute ischaemic stroke, offering promising insights for stroke treatment. Proud of our researchers!🧠 #StrokeResearch #ClinicalTrials Read Here ⬇️
eso-stroke.org/resources/pa...

BlueSky auto-captioned this as “A room with people sitting around tables having discussions” - which at one level is pretty much what happened today . . . but on another level we planned the next 5 years of UK Clinical Trials Units strategy!

Homeward bound from a fabulous Directors meeting for @ukctunetwork.bsky.social. Lots of discussions about sustainability, funding and policy. Loads to think about for our strategic priorities.

Shared this on Twitter this morning - and joined BlueSky this afternoon. First post - nice collaboration on Scottish nationwide diabetes data with Samira Bell @ University of Dundee. Innovative methodology and challenges received wisdom on withdrawing metformin after acute illness.